2023, Vol 23, No 3
Review
The mechanism of action of anti-CD20 monoclonal antibodies used in the treatment of multiple sclerosis
Marcin P. Mycko
Aktualn Neurol 2023; 23 (3): 72–78
DOI: 10.15557/AN.2023.0012
Review
Why do we so rarely recognise and treat the primary progressive form of multiple sclerosis?
Waldemar Brola
Aktualn Neurol 2023; 23 (3): 79–83
DOI: 10.15557/AN.2023.0013
Review
OPERA and ORATORIO – how the world has been changed by “music”
Ewa Krzystanek, Robert Bonek
Aktualn Neurol 2023; 23 (3): 84–92
DOI: 10.15557/AN.2023.0014
Case report
Long-term efficacy of ocrelizumab in the treatment of patients with multiple sclerosis – case reports
Ewa Krzystanek, Waldemar Brola, Marcin Wnuk
Aktualn Neurol 2023; 23 (3): 93–104
DOI: 10.15557/AN.2023.0015
Review
Safety profile and adherence to treatment with ocrelizumab in multiple sclerosis – long-term observations
Anna Pokryszko-Dragan
Aktualn Neurol 2023; 23 (3): 105–110
DOI: 10.15557/AN.2023.0016
Review
The role of ocrelizumab in recommendations and in the Polish therapeutic programme
Katarzyna Joanna Kubicka
Aktualn Neurol 2023; 23 (3): 111–117
DOI: 10.15557/AN.2023.0017
Review
New directions in ocrelizumab therapy in multiple sclerosis: higher doses and subcutaneous therapy
Krzysztof Selmaj, Igor Selmaj
Aktualn Neurol 2023; 23 (3): 118–124
DOI: 10.15557/AN.2023.0018
